The paper introduces MedPromptX, a clinical decision support system using multimodal large language models (MLLMs), few-shot prompting (FP), and visual grounding (VG) for chest X-ray diagnosis, integrating imagery with EHR data. MedPromptX refines few-shot data dynamically for real-time adjustment to new patient scenarios and narrows the search area in X-ray images. The study introduces MedPromptX-VQA, a new visual question answering dataset, and demonstrates state-of-the-art performance with an 11% improvement in F1-score compared to baselines.
A retrospective study in Abu Dhabi, UAE, developed a machine learning-based prognostic system to predict the risk of seven complications in COVID-19 patients using data from 3,352 patient encounters. The system, trained on data from the first 24 hours of admission, achieved high accuracy (AUROC > 0.80) in predicting complications like AKI, ARDS, and elevated biomarkers in geographically split test sets. The models primarily used gradient boosting and logistic regression.
Agathe Guilloux, a professor in Data Science at Evry Paris Saclay University, presented on machine learning algorithms for precision medicine at MBZUAI. Her talk covered the main challenges of precision medicine and how AI can address them. She also discussed algorithms developed for decision support tools. Why it matters: This highlights MBZUAI's role as a platform for discussing advanced AI applications in healthcare, even when the research is not directly conducted in the GCC.
This article discusses the use of artificial intelligence in precision oncology, particularly in understanding individual tumor mechanisms and aiding clinical decision-making. Dr. Xinghua Lu, with extensive experience in medicine and biomedical informatics, will present research on individualized Bayesian causal inference methods for investigating oncogenic mechanisms. These methods aim to provide clinical decision support at the cellular, tumor, and patient levels. Why it matters: AI-driven precision oncology can enable more personalized and effective cancer treatments, improving patient outcomes in the region and globally.
MBZUAI is developing AI algorithms to intelligently process data from wearables and home sensors for remote patient monitoring. The algorithms aim to analyze multiple strands of health data to provide a more comprehensive view of a patient's health, distinguishing between genuine emergencies and benign situations. MBZUAI's provost, Professor Fakhri Karray, believes this approach could handle 20-25% of diagnoses virtually, reducing the burden on healthcare systems. Why it matters: This research could significantly improve healthcare efficiency and accessibility in the UAE and beyond by enabling more effective remote patient monitoring and reducing unnecessary hospital visits.
MBZUAI researchers developed MedAgentSim, a simulated hospital environment to evaluate AI diagnostic abilities. The simulation uses LLM-powered agents to mimic doctor-patient conversations, providing a dynamic assessment of diagnostic skills. The system includes doctor, patient, and evaluator agents that interact within the simulated hospital, making real-time decisions. Why it matters: This research offers a more realistic evaluation of AI in clinical settings, addressing limitations of current benchmarks and potentially improving AI's use in healthcare.
MBZUAI researchers led by Dr. Mohammad Yaqub are developing AI algorithms for real-time medical diagnoses, including tools for multiple sclerosis and congenital heart disease. The team developed ScanNav, an AI fetal anomaly assessment system licensed by GE Healthcare for Voluson SWIFT ultrasound machines. ScanNav assists doctors during anomaly scans after 20 weeks of gestation to check for conditions like heart issues and spina bifida. Why it matters: This research has the potential to significantly improve the speed and accuracy of medical diagnoses in the UAE and beyond, addressing critical gaps in healthcare.
Eduardo da Veiga Beltrame, bioinformatics lead at ImYoo (a Caltech spinout), presented on scalable methods for single-cell omics data analysis, including kallisto|bustools and scvi-tools. He highlighted their use in ImYoo's decentralized longitudinal study on Inflammatory Bowel Disease (IBD), where patients self-collect capillary blood samples. Beltrame also discussed his research on STEM education programs in Brazil as a visiting scholar at UC Berkeley. Why it matters: This highlights the growing trend of decentralized clinical studies leveraging advanced single-cell technologies for precision medicine, showcasing the potential of remote data collection and analysis in understanding complex diseases.